Evidence map›Paper›PMID 35475325›Full record

ArticleClinical and translational medicine2022

Cyclin C: A new responser for chemosensitivity in cancer.

Shuai Fang, Xiaofeng Jin, Chengwei Zhou, Zhaohui Gong

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Cyclin C: A new responser for chemosensitivity in cancer.Clinical and translational medicine · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuai FangDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Xiaofeng JinDepartment of Biochemistry and Molecular Biology, Ningbo University School of Medicine, Ningbo, China.
Chengwei ZhouDepartment of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Zhaohui GongDepartment of Biochemistry and Molecular Biology, Ningbo University School of Medicine, Ningbo, China.ORCID 0000-0002-5662-2752
Ningbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The resistance to cisplatin-based chemotherapy is a common cause of poor prognosis in cancer patients. Cisplatin stimulation causes cyclin C translocating to mitochondria, and in turn induces mitochondrial fission. However, little is known about the role of cyclin C in mitochondrial dysfunction in cancer cells challenged with cisplatin. In the present commentary, we bring to the attention of readers the recent report by Jiang et al which revealed the importance of ubiquitylation and translocation of cyclin C in gastric cancer cells in response to cisplatin stimulation for mitochondrial stability. This finding provides new insights into exploring the novel mechanisms of chemoresistance and developing the new chemotherapy synergistic agents in the era of precision oncology.

Indexed as

Antineoplastic AgentsCyclin CStomach NeoplasmsApoptosisCisplatinDrug Resistance, NeoplasmHumansPrecision MedicineAntineoplastic AgentsCCNC protein, humanCisplatinCyclin Cchemotherapycyclin Cgastric cancer

Identifiers

PMID35475325
PMCPMC9042672
OpenAlexW4224937818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.